Table 3.
Changes in laboratory results after 12 months of MHT.
| Transdermal MHT (n = 75) | Oral MHT (n = 293) | |||
|---|---|---|---|---|
| Baseline | 12 months | Baseline | 12 months | |
| AST | 20.9 ± 6.7 | 20.8 ± 5.3 | 22.1 ± 8.7 | 22.2 ± 7.8 |
| ALT | 19.0 ± 8.6 | 17.6 ± 6.7 | 19.0 ± 10.9 | 18.2 ± 9.4 |
| ALP | 55.0 ± 17.2 | 54.3 ± 16.4 | 53.8 ± 16.2 | 49.7 ± 12.1*,† |
| ɣ-GT | 24.5 ± 23.6 | 24.3 ± 23.8 | 18.8 ± 18.7 | 18.5 ± 17.2 |
| Total bilirubin | 0.7 ± 0.3 | 0.7 ± 0.3 | 0.6 ± 0.2 | 0.6 ± 0.3 |
| Fibrinogen | 282.9 ± 68.6 | 286.2 ± 55.8 | 278.0 ± 68.6 | 288.0 ± 51.6* |
| Total cholesterol | 194.0 ± 31.6 | 192.3 ± 32.0 | 202.3 ± 45.7 | 195.4 ± 31.7* |
| Triglycerides | 107.4 ± 62.1 | 104.6 ± 51.1 | 104.4 ± 59.2 | 118.4 ± 98.1* |
| HDL-C | 57.9 ± 10.0 | 65.4 ± 16.6 | 59.9 ± 9.8 | 70.5 ± 16.1*,† |
| LDL-C | 116.0 ± 29.3 | 116.0 ± 32.0 | 119.7 ± 33.3 | 114.6 ± 28.8* |
| FBS | 91.3 ± 13.5 | 90.8 ± 15.1 | 89.2 ± 10.3 | 88.7 ± 9.1 |
| Insulin | 6.1 ± 2.3 | 5.5 ± 3.7 | 5.5 ± 3.1 | 5.3 ± 3.4 |
| HbA1c | 5.6 ± 0.5 | 5.6 ± 0.6 | 5.4 ± 0.5 | 5.5 ± 0.5 |
| HOMA-IR | 1.4 ± 0.6 | 1.3 ± 1.0 | 1.3 ± 0.8 | 1.2 ± 0.8 |
| eGFR | 89.8 ± 16.1 | 85.2 ± 13.9 | 87.2 ± 13.4 | 86.6 ± 14.0 |
| Uric acid | 4.3 ± 0.8 | 4.2 ± 0.9 | 4.3 ± 0.9 | 4.3 ± 0.8 |
| CRP | 0.08 ± 0.09 | 0.11 ± 0.24 | 0.10 ± 0.14 | 0.12 ± 0.01 |
Data are presented as mean ± standard deviation.
*P < 0.05 based on paired t test, within each treatment; †P < 0.05 based on t test between the two treatments.
MHT menopausal hormone therapy, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, ɣ-GT gamma-glutamyltransferase, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, FBS fasting blood sugar, HbA1c hemoglobin A1c, HOMA-IR homeostatic model assessment for insulin resistance, eGFR estimated glomerular filtration rate, CRP,C-reactive protein.